000			01998 a2200529 4500
005			20250517054727.0
264		0	_c20160801
008			201608s 0 0 eng d
022			_a1769-6690
024	7		_a10.1016/j.medmal.2015.07.003 _2doi
040			_aNLM _beng _cNLM
100	1		_aChidiac, C
245	0	0	_aUpdate on a proper use of systemic fluoroquinolones in adult patients (ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin. SPILF.). _h[electronic resource]
260			_bMedecine et maladies infectieuses _cSep 2015
300			_a348-73 p. _bdigital
500			_aPublication Type: Journal Article; Practice Guideline
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAnti-Bacterial Agents _xadverse effects
650	0	4	_aAntibiotic Prophylaxis
650	0	4	_aBacterial Infections _xdrug therapy
650	0	4	_aBacterial Proteins _xantagonists & inhibitors
650	0	4	_aBiotransformation
650	0	4	_aChemical and Drug Induced Liver Injury _xetiology
650	0	4	_aChild
650	0	4	_aContraindications
650	0	4	_aDNA Gyrase _xgenetics
650	0	4	_aDNA Topoisomerase IV _xgenetics
650	0	4	_aDrug Resistance, Multiple, Bacterial _xgenetics
650	0	4	_aFemale
650	0	4	_aFluoroquinolones _xadverse effects
650	0	4	_aFrance
650	0	4	_aGastrointestinal Diseases _xchemically induced
650	0	4	_aHumans
650	0	4	_aLong QT Syndrome _xchemically induced
650	0	4	_aMale
650	0	4	_aMutation
650	0	4	_aPhotosensitivity Disorders _xchemically induced
650	0	4	_aPregnancy
650	0	4	_aPregnancy Complications, Infectious _xdrug therapy
650	0	4	_aTendinopathy _xchemically induced
650	0	4	_aTissue Distribution
650	0	4	_aTopoisomerase II Inhibitors _xadverse effects
650	0	4	_aYoung Adult
773	0		_tMedecine et maladies infectieuses _gvol. 45 _gno. 9 _gp. 348-73
856	4	0	_uhttps://doi.org/10.1016/j.medmal.2015.07.003 _zAvailable from publisher's website
999			_c25320919 _d25320919